Results 201 to 210 of about 10,450,606 (297)

Drug-Intervention Lag Phase Between Low-Density Lipoprotein-Cholesterol Lowering and Coronary Plaque Stabilization. [PDF]

Circ Rep
Takahashi N, Iwata H.
europepmc   +1 more source

The integrated Lei‐CNS PBPK‐PD model effectively predicts clozapine brain disposition and D2 receptor occupancy in humans

British Journal of Clinical Pharmacology, EarlyView.
Aim Clozapine, used for treatment‐resistant schizophrenia, has a narrow therapeutic window and highly variable plasma pharmacokinetics (PK), necessitating careful monitoring. Direct measurement of unbound brain PK in humans is unethical. To develop a physiologically based pharmacokinetic–pharmacodynamic (PBPK‐PD) model to predict clozapine brain ...
Mengxu Zhang, Thomas I. F. H. Cremers, Vivi Rottschäfer, Elizabeth C. M. de Lange   +3 more
wiley   +1 more source

Real-World Low-Density Lipoprotein Cholesterol Control After Transitioning From Evolocumab to Inclisiran. [PDF]

Circ Rep
Tabata T, Chinen T, Nakamura K.
europepmc   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

When Literature Priors Are Removed: Clinical Rank Shifts and Transancestral Stability in Antipsychotic Low-Density Lipoprotein (LDL)-Risk Modelling. [PDF]

Cureus
Cheung N, Cheung HK, Yu YW, Tsang YY.
europepmc   +1 more source

Purification of Advanced Therapeutics by Flow‐Through Pseudo‐Affinity Chromatography: Bi‐Specific mABs, Fc Fusion Proteins, and Adeno‐Associated Viruses

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Modern biopharmaceutical manufacturing requires purification platforms capable of processing structurally and functionally diverse products while addressing the challenge of removing persistent and high‐risk host cell proteins (HCPs).
Wenning Chu, Eduardo Barbieri, Arianna Minzoni, Shriarjun Shastry, Jacob P. LeBarre, Qingbo Shu, Taufika Williams, Xuanwen Li, Divya Chandra, Xuankuo Xu, Jerome Bill, David Roush, Joseph Taris, Patrick Gilbert, Andre Kiesewetter, Oliver Rammo, Michael Schulte, Christopher Major, Trina Mouchahoir, Steven Cramer, Cristiana Boi, Ruben G. Carbonell, Abraham Lenhoff, Stefano Menegatti   +23 more
wiley   +1 more source

Correction to: Challenges in the Choice of Nonstatin Medications for Low-Density Lipoprotein-C Lowering for Cardiovascular Risk Reduction. [PDF]

J Am Heart Assoc
europepmc   +1 more source

Lipoprotein X: A Cause for Misleading Levels of Low-Density Lipoprotein. [PDF]

JACC Case Rep
Lee R, Baum S, Roman T, Joshi-Guske P, Aggarwal M.   +4 more
europepmc   +1 more source

Engineering Stable Lentiviral Vector Producer Cells Improves LVV Production

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Stable lentiviral vector producer cell lines represent a promising platform for scalable and cost‐efficient vector manufacturing, yet their productivity is often limited by intrinsic host‐cell constraints. In this study, we aimed to identify cellular factors restricting LVV production in stable doxycycline‐inducible GPRTG producer cell lines ...
Jona Röscheise, Lena‐Marie Eberle, Holger Laux, Kerstin Otte   +3 more
wiley   +1 more source

Friedewald and Martin-Hopkins formulae for estimating low-density lipoprotein cholesterol in a Malagasy population. [PDF]

Afr J Lab Med
Rakotonjafiniarivo FH, Antsonantenaina T, Rakotomalala MS, Andriambelo RD, Ranaivosoa MK.   +4 more
europepmc   +1 more source